BACKGROUND: The differential diagnosis of acute chest pain is challenging, especially in patients with normal ECG findings, and may include coronary thrombosis or pulmonary emboli. The aim of this study was to investigate the novel fibrin-specific contrast agent EP-2104R for molecular targeted MR imaging of coronary thrombosis and pulmonary emboli. METHODS AND RESULTS: Fresh clots were engineered ex vivo from human blood and delivered in the lungs and coronary arteries of 7 swine. Subsequent molecular MR imaging was performed with a navigator-gated free-breathing and cardiac-triggered 3D inversion-recovery black-blood gradient-echo sequence before and after systemic administration of 7.5 micromol/kg EP-2104R. Two swine served as the control group. MR images were analyzed by 2 investigators, and contrast-to-noise ratio and gadolinium concentration in the clots were assessed. Before contrast media application, no thrombi were visible. After contrast administration, all 32 pulmonary emboli, 3 emboli in the right heart, and 5 coronary thrombi were selectively visualized as white spots with a mean contrast-to-noise ratio of 32+/-19. The average gadolinium concentration from all 3 types of thrombi was 144+/-79 micromol/L. CONCLUSIONS: Molecular MR imaging with the fibrin-targeted contrast-agent EP-2104R allows selective visualization of acute coronary, cardiac, and pulmonary thrombi.
BACKGROUND: The differential diagnosis of acute chest pain is challenging, especially in patients with normal ECG findings, and may include coronary thrombosis or pulmonary emboli. The aim of this study was to investigate the novel fibrin-specific contrast agent EP-2104R for molecular targeted MR imaging of coronary thrombosis and pulmonary emboli. METHODS AND RESULTS: Fresh clots were engineered ex vivo from human blood and delivered in the lungs and coronary arteries of 7 swine. Subsequent molecular MR imaging was performed with a navigator-gated free-breathing and cardiac-triggered 3D inversion-recovery black-blood gradient-echo sequence before and after systemic administration of 7.5 micromol/kg EP-2104R. Two swine served as the control group. MR images were analyzed by 2 investigators, and contrast-to-noise ratio and gadolinium concentration in the clots were assessed. Before contrast media application, no thrombi were visible. After contrast administration, all 32 pulmonary emboli, 3 emboli in the right heart, and 5 coronary thrombi were selectively visualized as white spots with a mean contrast-to-noise ratio of 32+/-19. The average gadolinium concentration from all 3 types of thrombi was 144+/-79 micromol/L. CONCLUSIONS: Molecular MR imaging with the fibrin-targeted contrast-agent EP-2104R allows selective visualization of acute coronary, cardiac, and pulmonary thrombi.
Authors: Andrew F Kolodziej; Shrikumar A Nair; Philip Graham; Thomas J McMurry; Robert C Ladner; Charles Wescott; Daniel J Sexton; Peter Caravan Journal: Bioconjug Chem Date: 2012-02-09 Impact factor: 4.774
Authors: L Chaabane; L Tei; L Miragoli; L Lattuada; M von Wronski; F Uggeri; V Lorusso; S Aime Journal: Mol Imaging Biol Date: 2015-12 Impact factor: 3.488
Authors: Ilknur Ay; Francesco Blasi; Tyson A Rietz; Nicholas J Rotile; Sreekanth Kura; Anna Liisa Brownell; Helen Day; Bruno L Oliveira; Richard J Looby; Peter Caravan Journal: Circ Cardiovasc Imaging Date: 2014-04-28 Impact factor: 7.792
Authors: Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan Journal: Mol Pharm Date: 2013-01-30 Impact factor: 4.939
Authors: Elyse D Bernard; Michael A Beking; Karunanithi Rajamanickam; Eve C Tsai; Maria C Derosa Journal: J Biol Inorg Chem Date: 2012-08-19 Impact factor: 3.358